Literature DB >> 6148523

"Pap" smear and the risk of cervical neoplasia: quantitative estimates from a case-control study.

C La Vecchia, S Franceschi, A Decarli, M Fasoli, A Gentile, G Tognoni.   

Abstract

The relation between Papanicolau ("Pap") smear and the risk of cervical neoplasia was evaluated in a case-control study in which 145 women with cervical intra-epithelial neoplasia (CIN) were compared with 145 age-matched outpatient controls, and 191 cases of invasive cervical cancer were compared with 191 control subjects in hospital for acute conditions unrelated to any of the established or suspected risk factors for cervical cancer. Compared with women with no previous screening smear, the relative risk (RR) estimate for invasive cancer was 0.44 (with 95% confidence interval [CI] = 0.24-0.80) for those who had had one smear and 0.20 (95% CI = 0.13-0.32) for those who had had two or more smears. The corresponding estimates for CIN were 0.27 (95% CI = 0.10-0.71) and 0.12 (95% CI = 0.06-0.25), respectively. The risk estimates for intervals of more than 5, 3-5, and less than 3 years were 0.36, 0.18, and 0.10 for invasive cancer, and 0.45, 0.31, and 0.07 for CIN. These results were not materially modified by adjustment for the major risk factors for cervical cancer, such as indicators of socioeconomic status and sexual habits. According to the estimates of this study, 64% of invasive cervical cancers could be prevented by screening at intervals of more than 5 years, an additional 18% by reducing the interval to 3-5 years, and a further 8% to less than 3 years.

Entities:  

Mesh:

Year:  1984        PMID: 6148523     DOI: 10.1016/s0140-6736(84)90705-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  21 in total

Review 1.  Quantitative approaches to the evaluation of screening programs.

Authors:  N E Day
Journal:  World J Surg       Date:  1989 Jan-Feb       Impact factor: 3.352

2.  Invasive cervical cancer among American Indian women in the Northern Plains, 1994-1998: incidence, mortality, and missed opportunities.

Authors:  Richard F Leman; David Espey; Nathaniel Cobb
Journal:  Public Health Rep       Date:  2005 May-Jun       Impact factor: 2.792

Review 3.  Report of a National Workshop on Screening for Cancer of the Cervix.

Authors:  A B Miller; G Anderson; J Brisson; J Laidlaw; N Le Pitre; P Malcolmson; P Mirwaldt; G Stuart; W Sullivan
Journal:  CMAJ       Date:  1991-11-15       Impact factor: 8.262

4.  Recommendations on screening for cervical cancer.

Authors:  James Dickinson; Eva Tsakonas; Sarah Conner Gorber; Gabriela Lewin; Elizabeth Shaw; Harminder Singh; Michel Joffres; Richard Birtwhistle; Marcello Tonelli; Verna Mai; Meg McLachlin
Journal:  CMAJ       Date:  2013-01-07       Impact factor: 8.262

5.  Twenty years' screening for cancer of the uterine cervix in Great Britain, 1964-84: further evidence for its ineffectiveness.

Authors:  M F Murphy; M J Campbell; P O Goldblatt
Journal:  J Epidemiol Community Health       Date:  1988-03       Impact factor: 3.710

6.  The pap smear and cervical cancer screening.

Authors:  T J Elmslie
Journal:  Can Fam Physician       Date:  1987-01       Impact factor: 3.275

7.  A centralised cytology screening programme for cervical cancer in Florence.

Authors:  D Palli; S Carli; S Cecchini; A Venturini; G Piazzesi; E Buiatti
Journal:  J Epidemiol Community Health       Date:  1990-03       Impact factor: 3.710

8.  A monoclonal antibody against basal cells of human epidermis. Potential use in the diagnosis of cervical neoplasia.

Authors:  V B Morhenn; A B Schreiber; O Soriero; W McMillan; A C Allison
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

9.  A case-control study of cervical cancer screening in north east Scotland.

Authors:  J E Macgregor; S M Moss; D M Parkin; N E Day
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-25

10.  Chronic disease as a barrier to breast and cervical cancer screening.

Authors:  C I Kiefe; E Funkhouser; M N Fouad; D S May
Journal:  J Gen Intern Med       Date:  1998-06       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.